Business Context and Reporting Period
This Form 8-K was filed by Stereotaxis, Inc. on January 23, 2006, reporting events that occurred on January 12, 2006. The filing details a significant commercial milestone for the company's Niobe Magnetic Navigation System in the United States.
Key Financial Metrics
The filing text does not provide specific financial data regarding revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on operational and clinical milestones rather than financial performance.
Material Changes and Operational Milestones
The primary material event is the successful treatment of cardiac arrhythmias at three leading U.S. electrophysiology sites using the CELSIUS RMT Diagnostic and Ablation Catheter in conjunction with the Stereotaxis Niobe System. This marks the first U.S. use of this catheter, which received FDA approval in December 2005.
- Market Expansion: The success expands the Niobe System's U.S. applications from diagnostic and device delivery procedures into the therapeutic market for minimally invasive endocardial ablation.
- Procedure Volume: During the week of January 2, 2006, a total of 15 procedures were completed across the Cleveland Clinic, Baptist Memorial Hospital-Memphis, and St. Elizabeth's Medical Center of Boston.
- Procedures Performed: Successful treatments included complex AVNRT ablation, AV node ablation, Atrial Tachycardia Ablation, Wolff-Parkinson-White Syndrome treatment, and Bi-Ventricular pacing lead placements.
Outlook, Management Commentary, and Risks
Market Outlook: Management estimates the worldwide market for these procedures comprises more than 400,000 procedures annually, with approximately 70% conducted in the U.S. The market is described as experiencing rapid growth.
Competitive Advantages: Clinical feedback suggests the Niobe system reduces physician exposure to imaging radiation and enhances patient safety through "soft-touch" contact, potentially reducing the risk of vessel or tissue perforation.
Regulatory Status: Core components have received regulatory clearance in the U.S. and Europe. The CELSIUS catheter has held CE Mark authorization in Europe since March 2005.
Key Facts for Investor Verification
- Confirm the commercial availability and reimbursement status of the CELSIUS RMT Diagnostic and Ablation Catheter in the U.S. following FDA approval.
- Verify the adoption rate of the Niobe System at other U.S. centers beyond the initial three sites mentioned.
- Assess the competitive landscape for magnetic navigation systems in the 400,000+ procedure global market.
- Review upcoming financial reports to determine the revenue impact of entering the therapeutic ablation market.